- Home
- Publications
- Publication Search
- Publication Details
Title
Secukinumab in the treatment of psoriasis: an update
Authors
Keywords
-
Journal
Immunotherapy
Volume 9, Issue 3, Pages 229-238
Publisher
Future Medicine Ltd
Online
2017-02-06
DOI
10.2217/imt-2016-0128
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
- (2017) Alice Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
- (2016) Vibeke Strand et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
- (2016) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study
- (2016) Shinichi Imafuku et al. JOURNAL OF DERMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
- (2015) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab: First Global Approval
- (2015) Mark Sanford et al. DRUGS
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
- (2015) Ulrich Mrowietz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
- (2015) Michele W L Teng et al. NATURE MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Chronically Inflamed Human Tissues Are Infiltrated by Highly Differentiated Th17 Lymphocytes
- (2014) J. Pene et al. JOURNAL OF IMMUNOLOGY
- Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial
- (2014) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
- (2014) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Antidrug antibodies in psoriasis: a systematic review
- (2013) L. Hsu et al. BRITISH JOURNAL OF DERMATOLOGY
- Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis
- (2013) Bruce W. Kirkham et al. IMMUNOLOGY
- Psoriasis: rationale for targeting interleukin-17
- (2012) G. Girolomoni et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
- (2012) P. Rich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study
- (2012) A. Chioato et al. Clinical and Vaccine Immunology
- IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion
- (2011) Danuta Gutowska-Owsiak et al. EXPERIMENTAL DERMATOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
- (2009) C. Johansen et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- (Re)defining biopharmaceutical
- (2008) Ronald A Rader NATURE BIOTECHNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started